ERBB2 and breast carcinoma: Metaplastic breast cancer accounts for less than 1% of invasive breast cancers worldwide, and is frequently triple negative, i.e., lacking expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2)1.